Mar 4, 2026 08:00AM

Mar 4, 2026 08:00AM

Mar 2, 2026 06:26AM

Feb 28, 2026 10:05AM

Feb 28, 2026 10:05AM

Feb 28, 2026 10:00AM

Feb 27, 2026 10:15AM KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients

Feb 27, 2026 10:04AM

Feb 27, 2026 10:00AM

Feb 25, 2026 04:30PM

Feb 25, 2026 04:30PM

Feb 25, 2026 12:37PM

Feb 25, 2026 12:37PM

Feb 20, 2026 06:00AM Barclays Starts Merck (MRK) at Overweight

Feb 19, 2026 05:27AM

Feb 19, 2026 05:15AM

Feb 12, 2026 06:45AM

Feb 12, 2026 06:45AM

Feb 11, 2026 06:45AM

Feb 11, 2026 06:45AM

Feb 10, 2026 04:52PM FDA approves Merck's (MRK) Keytruda for platinum-resistant ovarian cancer patients

Feb 10, 2026 03:56PM

Feb 6, 2026 08:00AM

Feb 3, 2026 06:30AM

Jan 15, 2026 06:02AM

Jan 12, 2026 02:00PM

Jan 12, 2026 09:56AM

Jan 7, 2026 06:50AM Merck starts phase 3 trial of KRAS G12C inhibitor with KEYTRUDA QLEX

Jan 7, 2026 06:50AM

Dec 19, 2025 03:52PM

Dec 19, 2025 02:40PM

Dec 19, 2025 02:39PM

Dec 17, 2025 03:36PM

Dec 17, 2025 06:45AM

Dec 17, 2025 06:45AM KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients w

Dec 12, 2025 08:45AM

Dec 12, 2025 08:45AM

Dec 9, 2025 09:28AM

Dec 9, 2025 08:52AM

Dec 4, 2025 12:06PM

Dec 4, 2025 12:05PM

Dec 2, 2025 11:24AM Top drug regulator Richard Pazdur set to leave FDA - Stat

Dec 2, 2025 08:30AM

Dec 1, 2025 06:45AM

Dec 1, 2025 06:45AM

Nov 24, 2025 08:00AM

Nov 21, 2025 04:12PM

Nov 21, 2025 04:12PM

Nov 21, 2025 01:24PM FDA approves Padcev plus Keytruda for certain patients with bladder cancer

Nov 21, 2025 12:09PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All